Despite these promising features, the safety of systemic CXCR2 inhibitors remains questionable as these small molecule drugs disrupt neutrophil chemotaxis and activation, resulting in an increased risk of developing neutropenia in cancer patients who already suffer from a compromised immune system [24,25]. Here, CXCR2 is linked to Decreased total neutrophil count.